Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals

NCT00218309 | Completed

• 2 other identifiers: NIDA-15462-1R01-15462-1
• Study Type: observational
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether the opportunity to take free supplemental hydromorphone (HYD) influences drug seeking behavior in heroin dependent individuals.

Conditions

Heroin Dependence; Opioid-Related Disorders

Keywords

opiate dependence

Interventions

Hydromorphone DRUG

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Current opiate dependence, verified by the structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
• Positive urine test for opiates
• Agreement to use adequate contraception for the duration of the study
• Able to read and write English

You may not qualify if:

• DSM-IV diagnosis of a psychiatric illness
• History of or current neurological disease, including structural brain abnormalities, seizures, infection, peripheral neuropathy, and head trauma
• History of cardiovascular disease, myocardial infarction, chest pain, edema, systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg, or diastolic blood pressure greater than 95 mm Hg
• Pulmonary disease, including obstructive pulmonary disease, cor pulmonale, tuberculosis, and asthma
• Systemic diseases, such as endocrinopathies, liver or kidney failure, myxedema, hypothyroidism, Addison's disease, or autoimmune disease
• Current alcohol or sedative drug dependence
• Pregnant or breastfeeding
• Currently receiving treatment for opioid dependence
• Known phobia of injections

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA): lead
• Wayne State University: collaborator

Study Sites (1)

Wayne State University

Detroit, Michigan, 48207, United States

Location

Related Publications (3)

• Woodcock EA, Lundahl LH, Burmeister M, Greenwald MK. Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study. Am J Addict. 2015 Jun;24(4):329-35. doi: 10.1111/ajad.12187. Epub 2015 Apr 24.

  PMID: 25911999 DERIVED

• Stoltman JJ, Woodcock EA, Lister JJ, Greenwald MK, Lundahl LH. Exploration of the telescoping effect among not-in-treatment, intensive heroin-using research volunteers. Drug Alcohol Depend. 2015 Mar 1;148:217-20. doi: 10.1016/j.drugalcdep.2015.01.010. Epub 2015 Jan 19.

  PMID: 25630964 DERIVED

• Greenwald MK, Steinmiller CL, Sliwerska E, Lundahl L, Burmeister M. BDNF Val(66)Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study. Addict Biol. 2013 Sep;18(5):836-45. doi: 10.1111/j.1369-1600.2011.00431.x. Epub 2012 Feb 16.

  PMID: 22339949 DERIVED

MeSH Terms

Conditions

Heroin Dependence; Opioid-Related Disorders

Interventions

Hydromorphone

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Morphine Derivatives; Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds

Study Officials

• Mark Greenwald, PhD

  Wayne State University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH

Study Record Dates

• First Submitted: September 16, 2005
• First Posted: September 22, 2005
• Study Start: September 1, 2003
• Study Completion: July 1, 2005
• Last Updated: January 12, 2017

Record last verified: 2006-05

Locations

US (1)